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INTRODUCTION 
                Emphysematous  Pyelonephritis  is a rare, potentially  fatal 
necrotising  infection of  renal parenchyma .  It is caused by gas forming 
organisms like  E.coli, Klebsiella, Proteus.   The pathogenesis of  
emphysematous  pyelonephritis is not clear.  It occurs mostly in diabetes 
mellitus patients. But it also occurs in patients with obstruction of urinary 
tract.   The other risk factors for emphysematous  pyelonephritis are renal 
stones and instrumentation of urinary tract.  
                  Patients may  present with varying clinical features like loin 
pain, fever, vomiting, renal failure, shock.  The case fatality ratio is very 
high.  However with the advent of  Computer tomography the diagnosis 
can be made at a earlier stage of the disease.  With aggressive management 
of emphysematous  pyelonephritis  with appropriate  antibiotics, surgical 
drainage and nephrectomy, if required the mortality has been decreased  in 
the last decade.   
                As it is a rare disorder, the  management protocols and  
prognosis are rarely been studied. In our study, we evaluate the 
predisposing factors clinical presentation, causative organism, mode of 
therapy of emphysematous  pyelonephritis  in type 2 diabetes mellitus 
patients. 
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AIM OF THE STUDY 
1. The aim of this study is to evaluate  the  
 Predisposing factors 
 Clinical features  
 Causative organism 
 Mode of therapy required for emphysematous pyelonephritis  in 
type 2 diabetes mellitus patients. 
2. To evaluate the outcome of emphysematous pyelonephritis in type 
2 Diabetes mellitus in our population. 
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REVIEW OF LITERATURE 
Diabetes mellitus is probably the most widely prevalent metabolic 
disorder among the world population.  The incidence of diabetes mellitus 
is increasing day by day both in global and Indian scenario.  The 
prevalence of diabetes is 2.8% in 2000, but this figure will reach 4.4% in 
2030 worldwide. 
WORLD WIDE SCENARIO OF DIABETES 
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Prevalence in Indian scenario: Increasing trend 
 
 
RISING TREND OF T2DM IN URBANIZED INDIAN CITIES AND THEIR 
PROJECTED OUTLOOK 
[]
 
               With India embracing both eastern and western lifestyle the 
prevalence of obesity has increased alarmingly, prevalence is between 10 
and 50% in various Indian cities. One study from urban Chennai has 
showed a prevalence rate of 22.8% in males and 31.8% in females
[74].
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               As of 2011 there are 61million diabetics in India. Recent Chennai 
Rural Urban Epidemiological Study [CURES] had showed a crude 
prevalence rate of 14.3% [ age adjusted],with in a span of 14 years the 
prevalence had increased alarmingly by 73%[75]. 
DIAGNOSTIC CRITERIA FOR DIABETES MELLITUS 
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   GLYCOSYLATED HEMOGLOBIN (HbA1C) 
            Glycation refers to non-enzymatic addition of a sugar residue to 
an amino group of a protein.  Hemoglobin, plasma proteins, lens 
protiens etc., may undergo glycolysation. HbA1C forms the major 
fraction (80%).  In     HbA1C  the  N-terminal valine residue of each 
beta chain gets glycated. 
            HbA1C gives a retrospective index of integrated plasma 
glucose values over a six to eight weeks period. HbA1C serves as a 
reliable indicator of diabetic control during the past 90 days, 
effectiveness of treatment and risk of development of  acute  or chronic 
complications.  Hence HbA1C should be performed in all patients with 
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diabetes during the initial visit and every three months to assess 
metobolic control . 
Normal HbA1C values and interpretations  
 Normal range     4.5 –  5.8% 
 Risk of  hypoglycemia  < 4.5% 
 Diabetic range    > 6.5% 
 Prediabetic range   5.8 – 6.5% 
HbA1C % Mean plasma glucose (mg/dl) 
5 97 
6 126 
7 154 
8 183 
9 212 
10 240 
11 269 
12 298 
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DIABETES AND KIDNEY 
Diabetes has become the most common cause for chronic kidney 
disease all over the world.  In type 1diabetes, nephropathy occurs 25 to 40 
years after diagnosis and his seen in about 25 to 40% of patients.  In type 2 
diabetes, nephropathy will be present in 5 to 10% of patients at the time of 
diagnosis itself.  The cumulative incidence is 25% after 20 years of 
diagnosis. 
Diabetic nephropathy is a clinical syndrome characterized by 
persistent albuminuria ( > 300 mg / 24 hours or > 200 mcg / min) on atleast 
2 occasions separated by 3 – 6 months.  Albuminuria   > 300 mg / 24 hours 
is equivalent to a total proteinuria  > 500 mg / 24 hours.  This is also called 
as macroalbuminuria.   Urine albumin excretion of 30 – 300 mg / 24 
hours or 20 – 200 mcg/ min is microalbuminuria. 
Stages of diabetic nephropathy 
Carl Eric Mogensen’s classical description in 1983 of the five stages 
of diabetic nephropathy was for type 1 diabetes mellitus.  However the 
general pattern remains the same for type 2 diabetes mellitus.  The stages 
are as follows: 
Stage 1 – Stage of renal hypertrophy and glomerular hyperfiltration  
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Stage 2 – Stage of apparent normalcy 
Stage 3 – Stage of microalbuminuria or incipient nephropathy 
Stage 4 – Stage of established nephropathy 
Stage 5 – End stage renal disease 
Pathogenesis of   diabetic nephropathy 
The primary insult to the kidneys is due to hyperglycemia. 
Hypertension and proteinuria worsens the nephropathy.  It is postulated 
that increase in glucose leads to oxygen free radicals generation that result 
in nephropathy.  Four pathways - protein C kinase pathway, polyol 
pathway, hexoaminase pathway and formation of advanced glycation end 
products result in over production of cytokines which induce fibrosis and  
increase vascular permeability.  Accumulation of protein in tubular cells 
initiates mesenchymal cell transformation leading to chronic tubular injury.   
Three main changes occur in diabetic nephropathy. First is 
thickening of glomerular basement membrane. Second is glomerular 
sclerosis.  Third is appearance of Kimmelstiel-wilson nodules. 
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INFECTIONS  ASSOCIATED  WITH  DIABETES  MELLITUS   
Infections associated with diabetes mellitus can be discussed under two 
headings. 
 Infections with an increased prevalence in patients with DM 
• Oral and esophageal candidiasis 
• Bateriuria and cystitis  
• Pyelonephritis and perinephric abscess 
• Surgical site infection 
• Cellulitis and osteomyelitis 
• Pyomyositis 
• Tuberculosis of  lung 
• Staphylococcal and gram negative pneumonia 
 Infections unique to patients with DM 
• Rhinocerebral mucormycosis  
• Malignant  otitisexterna 
• Synergistic necrotizing cellulitis 
• Fournier’s  gangrene 
• Emphysematous cystitis  
•  Emphysematous pyelitis 
• Emphysematous pyelonephritis 
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    EMPHYSEMATOUS PYELONEPHRITIS 
                   Emphysematous pyelitis is the term used to describe the 
presence of gas limited through renal excretory system.  Emphysematous 
cystitis is due to inflammation of bladder mucosa and its musculature.  
Emphysematous pyelonephritis is defined as necrotizing infection of renal 
parenchyma and its surrounding tissues.  Gas accumulates in renal 
parenchyma, collecting system or perinephric tissues.   It carries a 
mortality of 100% if  left untreated. 
History  and epidemiology emphysematous pyelonephritis  
                 Emphysematous pyelonephritis was first reported in 1898 by 
Kelly & Mac Cullum as a case of pneumaturia as they found it is a gas 
forming renal infection.  Since then various names like renal emphysema, 
pneumonephritis,  are used.  In 1962 Schultz & Kloferin  proposed the 
name  emphysematous Pyelonephritis.  
Epidemiology 
          The average age of presentation of patients with emphysematous 
pyelonephritis is 56 years, although the range may vary from 16 - 80 years.  
Females are affected more commonly than males. The reason for female 
preponderance   may be due to increased  risk of genitourinary infections 
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in them.  The male : female ratio is  7:1.  Right kidney is less commonly 
affected than the left may be  due to  preponderance of left sided urinary 
tract obstruction.  In ten percent of  cases both the kidneys are involved. 
             Almost all the patients are diabetic with poor blood sugar control 
with elevated glycosylated  hemoglobin.  Rarely few cases occurs in non – 
diabetic population .  Other risk factors for this rare disease are renal 
failure,  obstructed urinary tract, previous history of instrumentation, renal 
stones, polycystic kidneys.   The main cause of emphysematous 
Pyelonephritis in patients without diabetes is obstruction of  urinary tract. 
Etiology and pathogenesis  
It is caused by gas forming  organisms . E. coli is  the most common 
organism. 
Common organisms include: 
• Escherichia  coli  (68%) 
• Klebsiella  pneumonia   (24%) 
• Proteus  mirabilis 
•  Pseudomonas 
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Rare organisms include: 
• Clostridium perfrigens  
• Citrobacter 
• Aerobacter aerogenes   
• Candidiasis 
The exact mechanism of gas formation is not clear.  The proposed 
cause for gas chamber formation are  
• Increased gas production 
• Due to poor blood supply there is decreased transport of gas 
• Formation of gas chamber 
• Equilibrium of gas chamber  and tissue gas 
• Expansion or collapse of gas chamber 
Regarding the gas content many hypothesis are proposed.  Usually 
bacteria get their energy by fermentation of glucose through glycolytic 
pathway.  In 1889 nitrogen, hydrogen, and Carbondioxide were found in a 
patient with pneumaturia.   The gases demonstrated  are  
• Nitrogen -  60% 
• Hydrogen – 15% 
• Carbondioxide - 5% 
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• Oxygen – 5% 
• Rarely methane, ammonia are also demonstrated in some 
studies. 
Gas forming  organism follow two different pathways namely,  
1. Mixed fermentation -  E. coli, Klebsiella, Proteus – Carbon dioxide  
2. Butyric fermentation – Clostridium -  hydrogen 
 
Fig - Macroscopic appearance showing diffuse parenchymal necrosis 
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Fig -  Cut   cross section shows diffuse parenchymal necrosis and 
haemorhage 
              The  pathogenesis of  emphysematous pyelonephritis is poorly 
understood . Renal infarcts, thrombosis, abcess and necrosis are 
demonstrated in pathological specimen of emphysematous pyelonephritis.  
Four reasons are described for the occurrence of emphysematous 
pyelonephritis are 
  Bacteria that forms gas 
 Increased bacterial growth due to high blood sugar 
 Decreased tissue perfusion that leads to tissue ischemia 
and necrosis  
 Defective immune response 
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Fig -   Pathological specimen showing areas of renal infarction, vascular 
thrombosis in a patient with emphysematous pyelonephritis. 
 
Fig  - Histology showing renal  infarction and glomerularscelorsis 
 E. coli and emphysematous Pyelonephritis 
             E. coli is the most common organism  causing  both complicated 
(21 – 54%)  and uncomplicated  (70 – 95%) urinary tract infection.  It 
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accounts for 68% of cases of emphysematous Pyelonephritis.  The various 
mechanisms by which  E.coli  causes emphysematous pyelonephritis  are 
• O  serotypes  interfere with  compliment dependent  bacterial  
killing. 
• K antigens (capsular  polysaccharide)  or anti phagocytic and 
anti complimentary  
• P fimbriae  are mannose  resistant. The receptor binding adhesin 
at the tip of  P fimbriae is pab G and there are three classes of G 
– tip proteins.  Class II – tip adhesin is associated with 
emphysematous Pyelonephritis.  Class III– tip adhesin is 
associated with  cystitis. 
Other virulence factors of  E.coli  identified by Polymerase chain 
reaction: 
• iroN, iron – regulated  gene. 
• Iha, homologue adhesion  
• kpsMT, group II capsule 
• ompT,  outer membrane protease T 
• USP , uropathogenic protein 
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Clinical features  
           Most of the patients with emphysematous pyelonephritis  presents  
with pyrexia, pain over flank and vomiting.  These clinical features do not 
differentiate upper  urinary tract infection from emphysematous 
Pyelonephritis. Crepitus  over the flank area may occur in late stages, but is 
characteristic.    
            The initial presentations of late stages of emphysematous 
Pyelonephritis may be 
• Hypotension 
• Decreased platelet count 
• Altered sensorium 
• Worsening   renal function 
• Subcutaneous  emphysema 
• Pneumomediastinum 
              Associated comorbid conditions include alcoholism, diabetic 
ketosis, renal stones. Emphysematous pyelonephritis may complicate 
pregnancy.  It does not affect pediatric diabetic population.  High index of  
suspicion  is required for  early diagnosis of  this potentially fatal condition 
because late stages of  this disease is associated  with  higher mortality. 
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The clinical features, routine blood and urine investigations are mentioned 
in the following table.  
 
          
             If the patient presents with alteration of  sensorium , hypotension, 
elevated renal parameters,  low platelet count the prognosis is found to be  
poor.  Patients presenting with poor blood sugar control with diabetic 
ketosis also carry a poor prognosis.  If patients  have adequately  controlled  
blood sugar level and hence HbA1C carries good prognosis. 
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Laboratory  investigations 
            Complete blood count will show increased total count with 
neutrophilia with a left shift.  Platelet counts are decreased.  
Thrombocytopenia is one of the poor prognostic factors.  Peripheral smear 
study will suggest features of  sepsis.   
               Routine urine examinations will reveal plenty of  pus cells, 
albuminuria which may be either due to acute kidney injury or preexcisting 
diabetic nephropathy.  Urine spot protein creatinine ratio will be increased. 
Urine acetone positivity will suggest poor prognosis. 
             Urine culture will reveal the causative organism.  Urine culture is 
positive in most of the patients.  Antibiotics should be given according to  
sensitivity pattern.   E.Coli, Klebsiella, Proteus are the common organisms 
grown in urine culture.   
Blood sugar is elevated in most of the cases.  HbA1C value will 
reveal the past three months sugar control.  Usually HbA1C is elevated.  
Increased creatinine may suggest preexisiting diabetic nephropathy or 
acute renal injury.  Again increasing creatinine values carry grave 
prognosis.   
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            Blood culture is positive in forty to fifty percent of patients.  
Positive blood culture carries poor prognosis.   Antibiotics should be given 
according to sensitivity pattern.  Mixed culture pattern rarely occurs.  
Imaging studies 
           Patients should be stabilised with fluids and appropriate antibiotics 
before radiological investigations.   Emphysematous Pyelonephritis is 
classified radiologically using  plain X ray KUB, Ultrasonogram  KUB, 
non contrast CT  KUB . 
Plain X ray KUB 
Langston and Pfsiter described three main radiological patterns  
• Diffuse mottling of the renal parenchyma  
• Bubbly renal parenchyma surrounded by crescent shape gas in 
perinephric  space 
• Extension of gas through gerota fascia  
Michaeli suggested three stages  
• Stage I – Gas within renal parenchyma or in the perinephric 
tissue 
• Stage II – Gas is present in the kidney and its surroundings 
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• Stage III – Extension of gas through gerota fascia or bilateral 
disease 
 
Fig  - Stage III disease  involving  left kidney 
 
 
Fig -  Right kidney appears normal. Bowel gas shadow seen 
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Fig – Dark arrow shows 2 cm calcification in left ureteropelvic junction 
White arrows show small calcifications. shows  large air fluid  level in left 
upperpole .  
 
 
Fig – X ray shows bilateral  Emphysematous pyelonephritis Stage III 
disesase 
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Ultrasonogram KUB 
• Ultrasound findings. 
o High-amplitude echoes within renal sinus and/or renal 
parenchyma associated with "dirty" shadowing  
"Comet tail" reverberations 
o Kidney may be completely obscured by large amount of gas 
in perinephric space  
o Ring – down artifacts: air bubbles trapped in fluids 
o Top differential diagnosis  include: renal calculi, 
nephrocalcinosis,  papillary necrosis 
Wan et al described two distinct types using X ray, USG, CT 
Abdomen,  
Type I  -  Parenchymal destruction with streaky or mottled 
parenchymal gas with an absence of  fluid collection.  Mortality is upto 
sixty percent. 
Type II -  Renal or perirenal fluid collection with bubbly gas 
collection in the perinephric  space or in the collecting system.  Mortality 
is upto twenty percent. 
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Few images of  USG KUB are shown below 
 
Fig -    Long arrows shows multiple hyperechoic foci Small arrows 
shows dirty acoustic shadows   
           
 
Fig – Type II disease 
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Fig -   Long arrow shows high amplitude echoes represents air with 
fluid collection                 
 
 
Fig – Type I disease 
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CT KUB  
Noncontrast   CT KUB is the is the most sensitive investigation for 
the diagnosis of this disease.  It demonstrates the extent of disease, detects 
renal stone and points out obstruction of the urinary tract,  if present.  
Huang et al modified the staging proposed by Michaeli as follows  
 Class I – Gas confined to the collecting system 
 Class II – Gas confined to renal parenchyma 
 Class III A – Perinephric extension of  gas  
 Class III B -  Extension of gas beyond gerota fascia  
 Class IV – Bilateral EPN or EPN in single functioning  kidney 
 
Fig – Class I disease.  Gas in right renal pelvis 
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Fig – Class II disease. Gas in right renal parenchyma and right renal stone  
 
 
 
Fig – Class III disease EPN with perinephric extension and abscess 
formation involving left kidney  
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Fig – Class IV disease   Bilateral EPN 
 
 
                       Fig – Class I disease involving right kidney 
42 
 
 
     
Fig – Emphysematous pyelitis with pyonephrosis and situs inversus  
 
         Thus CT KUB is  not only the modality of choice for diagnosing 
emphysematous  pyelonephritis , it is also useful in identifying renal stones 
and any other obstruction ,if present.  It is also useful as a prognostic 
indicator. Class I and Class II disease carries good prognosis even if 
managed by medical treatment alone.  Class III A and Class III B requires 
surgical intervention.  Class IV carries  worst  prognosis.  So CT KUB is  
useful in planning  treatment for emphysematous pyelonephritis.   
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MANAGEMENT 
                 The treatment of  emphysematous pyelonephritis includes: 
1. Medical treatment 
2. Surgical treatment 
• Percutaneous drainage 
• Nephrectomy 
Medical treatment 
               Patients should be stabilised before  being  subjected to 
radiological procedures. Intravenous fluids, inotropes may be needed if 
they present with shock and hypotension.  Appropriate antibiotics should 
be started after taking necessary investigations .  Blood, platelets may be 
required for treating thrombocytopenia and septicaemia.  If  blood sugar is 
elevated insulin should be started.   Diabetic ketosis should be managed 
appropriately.   Elevated  renal parameters and worsening renal function 
may require renal replacement therapy in the form of hemodialysis.  Sepsis  
should be  aggressively treated.  Most of the patients with Class I and  
Class II will improve with appropriate medical treatment. But Class III and 
Class IV patients often requried surgical intervention.   
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 Surgical treatment  
          After stabilising the patient and  doing CT KUB the need of surigical 
intervention is decided.  Nowadays   with the availability of potent 
antibiotics the role of surigcal treatment has drastically decreased.  
However CT guided percutaneous drainage is required in case of localised 
pus collection.  This procedure has significantly reduced the mortality rate. 
Many recent studies have shown that emphysematous pyelonephritis can 
be sucessfully treated with antibiotics and renal replacement therapy  
alone.    Huang et al has  suggested that surgical intervention is required in 
late stages of emphysematous pyelonephritis.  Class IV EPN is potentially 
fatal.   But nephrectomy may be necessary  in Class III and Class IV 
patients .     
               Since patients with  emphysematous pyelonephritis may have 
associated diabetic nephropathy  and  chronic renal failure even after 
nephrectomy   they may require renal replacement therapy postoperatively.   
So the decision for nephrectomy should be judicially taken at the 
appropriatie time . 
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Chart  -  Algorithm for the management of  EPN. risk factors - 
thrombocytopenia , shock, altered sensorium, acute renal injuriy 
 
Prognostic factors  
       Poor prognostic factors are 
 Age more than 60 years 
 Long duration of  diabetes mellitus 
 Preexisting diabetic nephropathy 
 Associated immuno compromised state 
  Associated obstruction of urinary tract 
 Previous history of  instrumentation  
 Poor blood sugar control 
 High HbA1C value  
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 Diabetic ketosis at admission 
 Acute kidney injury 
 Altered sensorium 
 Thrombocytopenia 
 Hypotension 
 Comorbid illness like Coronary artery disease, hypertension 
 Casuative organism – Clostridium, pseudomonas, fungal org 
 Class III A and Class III B disease 
 Class IV disease 
              Mortality with medical therapy – 60 to 70% , can be reduced to 
20% with surgical drainage.  Patients who presents with sepsis, shock, 
renal failure have higher mortality. 
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MATERIALS AND METHODS 
1. Study design 
         It is a prospective and observational study. 
2. Study group 
          All type 2 diabetic patients presenting with urinary tract infection are 
screened with ultrasonogram of KUB.  Ultrasonogram proven 
emphysematous  pyelonephritis  are included in this study. 
3. Place of the Study 
        Kilpauk Medical College and Hospital  
4. Period of  Study 
       January 2011 – December 2012 
5. Collabarating Departments 
 Nephrology department  
 Diabetology department 
 Radiology department 
 Microbiology and biochemistry department  
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6. Conflict of interest 
      Nil 
7. Inclusion and exclusion  criteria  
        All type 2 diabetic patients (both males and females) more than 
eighteen years of age presenting with urinary tract infection are screened 
with ultrasonogram . Patients with ultrasonogram proven emphysematous  
pyelonephritis  are included in this study. Patients who do not satisfy the 
above criteria are excluded from this study.   
8. Consent 
    Informed consent is obtained from the patients before including them in 
the study. 
9. Methodology  
       a. Clinical Examination  
       b. Investigations done 
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 INVESTIGATIONS  DONE 
1. CBC with platelet count 
2. Urine albumin, sugar, deposits, acetone, spot PCR 
3. Urine culture and sensitivity 
4. Blood culture and sensitivity 
5. Blood sugar  
6. Blood urea 
7. Serum creatinine 
8. HbA1C 
9. Antibodies for HIV1 and HIV2 
10. X Ray  KUB 
11. USG  KUB 
12. CT  KUB 
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STATISTICAL ANALYSIS 
 
Mean values of all parameters in subgroups were calculated by 
independent sample-t-test. To compare the distributions of dichotomous 
data viz .gender, symptomatology, urine acetone, cultures for growth, need 
of dialysis/surgical intervention, Chi-square test was used. Association 
between variables was assessed by logistic regression model. Potential 
confounders were adjusted for. 
 
Pearson correlations were applied to evaluate the correlation 
between Emphysematous pyelonephritis and age, sex, history of 
fever,flank pain & UTI symptoms, UT obstruction, renal stones& use of 
instrumentation, blood culture & mode of therapy. All statistical analyses 
were performed using the SPSS package .A p-value of less than 0.05 was 
considered to be statistically significant. 
 
The analysis is done among various characteristics identified in a 
case series of emphysematous pyelonephritis. 
 
 
 
 
AGE
The age distribution of the study population is
Age More than   60 Yrs
Age Less than 60 Yrs
 
 
               The percentage of 
               The percentage of  patients of age more than 60 years 36%
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 DISTRIBUTION: 
 as follows:
Table 1 
 
 
Fig 1 
 patients of age less than 60 years 64% 
Age More than   60 Yrs
Age Less than 60 Yrs
 
9 
16 
 
 
 
SEX DISTRIBUTION OF STUDY GROUP:
The sex distribution of the study population is as follows:
 
The percentage of males 
The percentage of females 
 
Number of Males 
Number of Females 
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Table 2 
Fig 2 
 
– 24% 
– 76% 
Number of Males
Number of Females 
 
 
 
6 
19 
The correlation between age  and 
 
Age 
The mean age of patients who survived is 
of patients who died is 70.38 years . The correlation between the age of the 
patient and mortality outcome is 
higher the age of the patient, greater is the risk of mortality. 
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AGE 
mortality in the study population
Table 3 
Out come Mean 
Mortality 
Survival 
 
Fig 3 
53.12 years. The mean age 
statistically significant (p<0.05) i.e. 
 
Survival
. 
70.38 
53.12 
 
HISTORY OF FEVER
The correlation between history of fever  and m
 
 
 
 
   P =  0.484   
There is no statistical significance with regards to correlation 
between history of fever and mortality.
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Fever Absent 
54 
 
ortality in the study 
population 
Table 4:  
Fig 4 
 
Died
Fever Present
Fever Absent
Survival Mortality 
35.3 
64.7 
 
50 
50 
HISTORY OF 
The correlation between history of flank pain and mortality in the study 
 
  P =  0.484     Statisticall
There is no statistical significance with regards to correlation 
between history of  flank pain and mortality.
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Flank Pain Present 
Flank Pain Absent 
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FLANK PAIN 
population 
Table 5 
Fig 5 
y  not significant.       
 
Died
Flank Pain Absent
Flank Pain Present
Survival Mortality
94.10 
  5.90 
 
 
100 
    0 
The correlation between history of UTI symptoms  and mortality in the 
 
UTI Symptoms Present
UTI Symptoms Absent
 
 
P =  0.569     
There is no statistical significance with regards to correlation 
between history of UTI symptoms  and mortality
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UTI  SYMPTOMS 
study population 
Table 6 
Survival Mortality
 94.1 
   5.9 
Fig 6 
 
Died
UTI Symptoms Absent
UTI Symptoms Present
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12.5 
 
The correlation between duration of diabetes mellitus and 
 
Duration of DM 
There exist a statistically significant
between duration of diabetes mellitus and mortality
DM  in years in patients who survived is 
in years in  patients who 
0
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DURATION OF DM 
mortality
Table 7 
Out come Mean 
Mortality 22.38
Survival 
 
Fig 7 
 P = 0.000(< .05)   correlation 
. The mean duration 
 9.35. The mean duration 
died is  23.38. 
Survival
                              
 
9.35 
 
 of  
 of  DM  
HISTORY OF 
The correlation between 
 
UTO Present 
UTO Absent 
 
 P =  0.400   The correlation between 
and mortality  in the study population is not s
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URINARY TRACT OBSTRUCTION
history of urinary tract obstruction  and mortality
in the study population. 
Table 8 
Survival Mortality
11.8 
88.2 
Fig 8 
history of urinary tract obstruction 
tatistically significant
UTO Absent
Died
Survived
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HISTORY OF RENAL STONES
The correlation between renal stones and mortality in the study 
 
 
 
 
P = 0.170   Statistically not 
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population 
Table 9 
Fig 9 
significant.       
Renal Stones 
Absent
Died
Survived
Survival Mortality
   5.9 
 94.1 
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HISTORY OF INSTRUMENTATION
The correlation between 
 
Instrumentation Present
Instrumentation Absent
 
P = 0.170  The correlation between 
mortality  in the study population is not 
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history of instrumentation  and mortality
study population. 
Table 10 
Survival Mortality
   5.9 
 94.1 
Fig 10 
history of instrumentation  and 
 statistically  significant
Died
Instrumentation Absent
Instrumentation Present
  in the 
 
25 
75 
 
.       
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COMPLETE  BLOOD COUNT 
The correlation between complete blood count and mortality in the study 
population 
Table 11 
 Out come Mean 
CBC Mortality 18575.00 
Survival 13558.82 
P = 0.000 (< 0.05) Statistically Significant  
The correlation between 
 Out come
Platelet  
count 
Mortality
Survival
 
There exist a statistically significant
between platelet count and mortality. 
who survived is  18304.81.
who died is  54000. 
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PLATELET COUNT 
 platelet count  and mortality in the study 
population 
Table 12 
 Mean 
 54000.00
 18304.81
Fig 12 
 P = 0.000 (< 0.05) correlation 
The mean platelet count in 
 The mean platelet count  in years in 
Mortality
Survival
 
 
 
patients 
 patients 
The correlation between 
 
Urine Acetone Present
Urine Acetone Absent
There exist a statistically 
between urine acetone and mortality
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URINE ACETONE 
 urine acetone  and mortality in the study 
population 
Table 13 
Survival Mortality 
   5.9 
 94.1 
 
Fig 13 
significant  P = 0.000 (< 0.05) correlation 
. 
Urine 
Acetone 
Absent
Died
Survived
100 
0 
 
The correlation between 
 
Urine Spot PCR 
There exist a statistically 
between urine acetone and mortality
patients who survived is 
who died is  4.52. 
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URINE SPOT PCR 
 urine spot PCR and mortality in the study 
population 
Table 14 
Out come Mean 
Mortality 
Survival 
 
Fig 14 
significant  P = 0.000 (< 0.05) correlation 
.  The mean Urine spot PCR value  in 
 2.65. The mean Urine spot PCR value in 
Mortality
Survival
4.52 
2.65 
 
 patients 
The correlation between 
 
Blood Sugar 
There exists a statistically
between blood sugar values  and mortality
patients who survived is 
died is  454.25. 
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BLOOD SUGAR 
 blood sugar and mortality in the study population
Table 15 
Out come Mean 
Mortality 454.25
Survival 318.24
 
Fig 15 
 significant P = 0.000 (< 0.05)  correlation 
. The mean blood sugar  in 
 318.29.The mean blood sugar in  patients who 
Survival
 
 
 
 
SERUM CREATININE
The correlation between 
 
  Se Cr 
 
P = 0.386 The correlation between serum creatinine and mortality is not   
statistically  significant
survived is  4.74.The mean 
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 serum creatinine  and mortality in the
population 
Table 16 
Outcome Mean 
Mortality 6.99
Survival 4.74
Fig 16 
. The mean serum creatinine  in patients who 
serum creatinine  in  patients who died
Mortality
Survival
 study 
 
 
 
 is  6.99. 
The correlation between 
 
HbA1C 
 
The correlation between 
P = 0.000 (< 0.05) . The mean 
The mean HbA1C  in  patients who 
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HbA1C 
 HbA1C and mortality in the study population
Table 17 
Out come Mean 
Mortality 9.84
Survival 7.78
Fig 17 
 HbA1C and mortality is statistically s
HbA1C  in patients who survived is 
died is  9.84. 
Mortality
Survival
 
 
 
 
ignificant 
 7.78. 
URINE CULTURE AND SENSITIVITY
The correlation between 
 
E. Coli 
Klebsiella 
The correlation between 
statistically significant  
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 urine culture and sensitivity and mortality in the 
study population 
Table 18 
Survived Died 
100 
0 
 
Fig 18 
urine culture and sensitivity and mortality
P = 0.000 (< 0.05) 
Died
Klebsiella
E. Coli
37.5 
62.5 
 
 is 
URINE CULTURE AND SENSITIVITY
The organisms grown 
E. Coli
Klebsiella
 
In 80% of cases E.Coli is grown 
In 20% of cases Klebsiella is grown.
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in urine culture and sensitivity in our study 
population. 
Table 19 
 20 
 5 
Fig 19 
. 
 
E. Coli
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BLOOD CULTURE AND SENSITIVITY
The organism grown in blood culture and sensitivity 
No Growth 
E.Coli 
Klebsiella 
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in our study 
population. 
Table 20 
16 
4 
5 
Fig 20 
E.Coli Klebsiella
 
BLOOD CULTURE AND SENSITIVITY
The correlation between 
 
No Growth 
E.Coli 
Klebsiella 
The correlation between 
statistically significant 
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 blood culture and sensitivity and mortality in the 
study population 
Table 21 
Survival Mortality
94.1 
 5.9 
0 
 
Fig 21 
 blood culture and sensitivity  and mortality
 P = 0.000 (<0.05)    
E.Coli Klebsiella
Died
Survived
 
0 
37.5 
62.5 
 
 is 
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GRADING BY CT KUB 
The distribution of patients in the study population according to 
grading by CT KUB 
Table 22 
Class I 6 
Class II 10 
Class III A 4 
Class III B 5 
 
Fig 22 
 
The percentage of patients with Class I -  24% The percentage of 
patients with Class II – 40% The percentage of patients with 
Class III A – 16% The percentage of patients with Class III B – 
20%   
Class I
Class II
Class III A
Class III B
GRADING BY CT KUB
The correlation between grading by CT KUB and mortality in the 
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study population 
Table 23 
Survival Mortality
35.3 
58.8 
0 
5.9 
Fig 23 
Died
Class II
Class I
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GRADING BY CT KUB
 
There exists a statistically significant
KUB and mortality P = 0.000 (<0.05)
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Fig 24 
 correlation between grading by CT 
. 
Died
Class III B
Class III A
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MEDICAL TREATMENT 
The distribution of patients who received medical treatment 
 
 
 
 
 
 
 
 
Fig 25 
1. Meropenem 
2. Ceftriaxone 
3. Ceftriaxone and Piperacillin and tazobactam 
4. Imepenem 
5. Piperacillin and tazobactam 
6. Vancomycin 
7. Amikacin 
8. Meropenem and Ceftriaxone 
9. Meropenem and Vancomycin 
The correlation between dialysis and mortality in the study 
 
Hemodialysis 
Peritoneal dialysis 
 
There exists a statistically significant
mortality P = 0.000 (<0.05)   .
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DIALYSIS 
population 
Table 24 
Survival Mortality
17.6 
82.4 
Fig  26 
 correlation between dialysis and 
 
Died
Peritoneal dialysis
Hemodialysis
 
100 
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SURGICAL TREATMENT 
The distribution of patients who received surgical treatment 
Table 25 
No Intervention 18 
CT guided aspiration 3 
Partial Nephrectomy 2 
Nephrectomy 2 
 
Fig 27 
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SURGICAL TREATMENT 
The correlation between surgical treatment and mortality  
Table 26 
 Survival Mortality 
No Intervention 82.2 37.5 
CT guided aspiration 5.9 25 
Partial Nephrectomy 5.9 12.5 
Nephrectomy 0 25 
Fig 28 
 
There exists a statistically significant correlation between surgical 
treatment and morality P = 0.043 (<0.05) 
No Intervention
CT guided aspiration
Partial Nephrectomy
Nephrectomy
TREATMENT SUMMARY
The distribution of patients who received medical treatment alone 
and combined surgical treatment with mortality
Medical treatment 
Medical and surgical treatment
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Table 27 
 18 
 7 
Fig 29 
Medical treatment 
Medical and surgical 
treatment
 
SURVIVAL AND MORTALITY
The correlation between surgical treatment and mortality 
 
 
 
 
No of patients survived
No of  patients died
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Table 28 
Fig 30 
No of patients survived
No of  patients died
 17 
 8 
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DISCUSSION 
             In our study it is found that, 24% of the patients are above sixty 
years of age, 76% of patients are below sixty years of age.   All the above 
sixty years of age has severe disease and did not survive.  The mean age of 
patients who survived is 53.12 years .  The mean age of the patients who 
died is 70.38 years.  In a previous study the mean age of the patients was 
shown to be 58 years.  In that study, the mean age of patients who survived 
was 59 years .  The mean age of the patients who died was 67 years. 
 
In our study the ratio between affected female and male is 3.16:1.  
So there is female preponderance in our study.  In a previous study the 
female: male ratio was 5.6:1.   
 
Although the classical symptoms of this disease are fever and flank 
pain, urinary tract symptoms, in our study fever is not present in 32% of 
our patients. UTI symptoms are not present 4%.  In a previous study fever 
is not present in 21% of  patients. 
 
  In our study Urinary tract obstruction is present in 16% of the 
patients.  8% of them have urinary stricture and 8% have benign prostatic 
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hypertrophy.  8% of the patients have undergone transurethral resection of 
prostate.  In a previous study, it was shown that 24% of the patients had 
urinary tract obstruction.   
 
In our study, history of instrumentation is present in 12% of patients.  
8% of the patients have renal stones.  In a previous study, history of 
instrumentation is noted in 20% of the patients.    
 
In our study, the mean duration of diabetes mellitus is 16 years.  The 
mean duration of diabetes mellitus in patients who survived is 9.3 years.  
The mean duration of diabetes who died is 22.3 years .  The mean duration 
of diabetes mellitus in a previous study was about 20 years.   
 
In our study, leukocytosis is present in 95% of the patients. The 
mean total count in patients who survived is 13558. The mean total count 
in patients who died is 18575.  In a previous study 69% of the patients had 
leukocytosis. 
 
In our study, thrombocytopenia is present in 70% of the patients.  
The mean platelet count in patients who survived is 18304.  The mean 
platelet count in patients who died is 54000.  In a previous study 48% of 
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the patient had thrombocytopenia .  In that study, 36% of the patients with 
thrombocytopenia had survived and 64% of the patients died. 
 
In our study, 32% of the patients have positive urine acetone during 
admission.  All the patients with diabetic ketosis died.  
 
In our study, proteinuria is present in 85% of the patients.  In a 
previous study, proteniuria was present in 20% of the patients. 
 
In our study, the mean blood sugar in patients who survived is 
318.24.  The mean blood sugar in patients who died is 454.25.  87% of the 
patients who had diabetic ketosis at admission required surgical 
intervention. The mortality in patients with diabetic ketosis is 100%. 
 
In our study, the mean serum creatinine in patients who survived is 
4.74% and died is 6.99% . In a previous study 28% of the patients with 
elevated creatinine had died and 67% of the patients had survived. 
 
In our study the mean HbA1C in patients who survived is 7.78. The 
mean HbA1C who died is 9.84 .  85% of the patients had higher HbA1C.  
In a previous study, 70% of  patients had higher HbA1C. 
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In our study  E.coli is grown in urine culture  among 80% of the 
patients.  Klebsiella is grown in 20% .  The mortality is 100% in patients 
who had growth of Klebsiella and 15% in E.coli.  All the patients who had 
Klebsiella grown also had blood culture positive for Klebsiella.   
 
All the patients with growth of Klebsiella required surgical 
intervention.  There is no mixed culture positivity in our study.   In a 
previous study it is shown that E.coli is grown in 70% of the patients and 
Klebsiella in 28% of the patients.    
 
In our study, in blood culture 20% of the patients had Klebsiella 
grown.  E.coli is grown in 16% of the patients. No organism is grown in 
64% of the patients.  The mortality rates in patients with Klebsiella is 
100% and E.coli is 16%.  There is no mixture culture positivity.   
 
In our study, as we grade the disease by CT KUB,  Class I disease is 
present in 24%  of the patients and Class II in 40% of the patients.  All the 
patients who had Class I and Class II disease survived.  Class III A and 
Class III B is present in 16% and 20% respectively.  The mortality rate in 
Class III A and B is 75% and 100% respectively.  All the patients in Class 
III A and B requires surgical intervention.  In a previous study, the 
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mortality rate in patients with Class I and Class II is 0 and 10% 
respectively.  The mortality rate in patients with Class III A and B is 29% 
and 9% respectively.  The mortality rate in Class IV disease is 50%. 
         
In our study, all the patients require renal replacement therapy.  56% 
of the patients required peritoneal dialysis.  All  those patients  who 
required peritoneal dialysis survived.  44% of the patients required 
hemodialysis.  The mortality rate in patients  treated with hemodialysis is 
72%.   
 
In our study, all the patients are treated with appropriate antibiotic 
according to sensitivity pattern.  72% of the patients  does not require any 
surgical intervention.  The mortality rate of patients who are treated 
medical therapy alone is 11%.  But all of them belong to Class I and Class 
II group.   
 
In our study, 28%  of the patients required surgical therapy.  72% 
required medical treatment alone.  CT guided aspiration is done in 12% of 
the patients.  16%  of the patients required nephrectomy.  The mortality 
rate of the patients who underwent nephrectomy is  75%.  But all of them 
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belong to Class   III A and B groups.    All the patients in Class III A and B 
requires surgical intervention 
 
In a previous study, the over all  mortality rate is 32%. In the 
patients who died surgical intervention is done in  75% of patients.  25% of 
the patients were given only medical treatment(antibiotics).  In a previous 
study, the mortality rate in patients who are treated with antibiotics alone is 
38%.  The mortality rate in patients with surgical intervention is 60% 
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CONCLUSION 
To summarise the results of our study  
• Female patients are more commonly affected than males 
• Mortality due to the disease is greater in patients above sixty years of 
age. 
• Urinary tract obstruction is a separate risk factor for mortality in 
addition to Diabetes mellitus. 
• Mortality rate is more if the duration of diabetes is more than sixteen 
years.  
• Thrombocytopenia at presentation increases mortality rate. 
• All the patients who are dmitted with diabetic ketosis succumb to the 
illness. 
• Patients with  poor glycemic control reflected by high HbA1C  carried  
poor prognosis. 
• The commonest organism grown in urine culture is E.coli. Klebsiella 
is grown in 20% of the patient. 
• All patients with  klebsiella  grown in urine culture also have  blood 
culture positive for klebsiella.  
• The mortality rate is 100%  in klebsiella grown patients, when 
compared to E.coli (15%) 
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• 36% of the patients have sterile blood culture. 
• The mortality rate is high in patients who had blood culture positivity. 
(Klebsiella  - 100%, E.coli – 75%) 
• 64% of patients had Class I, Class II disease (as per CT KUB), all of 
them survived with medical treatment alone. 
• The mortality rate is 75% in Class III A and 100% in Class IIIB  
• All the patients required renal replacement therapy. 
• 72% of patients are treated by medical therapy alone, in which the 
mortality rate is 11% . 
• 28% of patients required surgical intervention , 12%  were treated 
with CT guided aspiration and 16% with nephrectomy. The mortality 
rate in  patients with nephrectomy 75% 
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As per the inference from our study 
          E.coli or Klebsiella infection in patients with diabetes mellitus is the 
corner stone for development of EPN.  Emphysematous pyelonephritis can 
be successfully as follows.  
 Although surgery was performed routinely, consensus now 
favors conservative therapy including placement of  catheter 
drainage nephrostomy for drainage.   
 All patients are treated with antibiotics and obstruction, if present 
should be relieved. 
 Class I disease can be treated with antibiotics alone.  
 Class II disease can be treated with antibiotics and percutaneous 
catheter drainage, if necessary.  
 Class III A and  III B disease at low risk  can be initially treated 
with antibiotics and percutaneous catheter drainage.  Sometimes  
nephrectomy may be necessary. 
 Class III A and III B disease at high risk require antibiotics plus 
nephrectomy. 
  Class IV disease   should initially  be treated with antibiotics and 
percutaneous catheter drainage. Nephrectomy is a last option. 
 Nephrectomy is indicated in all patients in whom  percutaneous 
catheter drainage is unsuccessful. 
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PROFORMA 
Personal data 
Name:        Age:      Sex: 
 
Address:              Occupation:   I.P No: 
 
Date of Admission:             Date of Discharge: 
 
History 
1. Fever 
 
2. Abdominal Pain, Flank Pain 
 
3. Vomiting 
 
4. Urinary Symptoms 
 
5. Other Symptoms 
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Past History 
History of  Diabetes Mellitus 
- Duration 
- Mode of Therapy 
- Control Status 
History of  Comorbid Illness 
- Hypertension 
- Coronary Artery Disease 
Previous Hospitalisation 
History of  Urinary tract obstruction 
History of  Renal Stones 
History of  Instrumentation, trauma 
History of  Immunosuppressive illness, drugs 
Family History 
                                  1. Diabetes Mellitus 
                                   2. Other Illness 
Personal History 
         Whether Smoker, Alcoholic 
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Clinical Examination  
Height                                                             Weight 
Vitals 
         Pulse Rate                                               Respiratory Rate 
 
        Blood Pressure                                        Temperature 
Systemic examination  
Abdomen 
1. Inspection 
2. Palpation 
3. Percussion 
4. Auscultation 
CVS 
 
RS 
 
CNS 
 
 
Investigation 
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1. CBC 
 
2. Urine Albumin                       Sugar   Spot PCR 
                 Deposit   Acetone 
            
3. Urine Culture and sensitivity 
           1                                           2                                       3 
4. Blood Culture and Sensitivity 
 
5. Blood urea and Serum Creatinine  
 
6. Hb1AC 
 
7. Antibodies for HIVI and HIV2 
 
8. X-RAY KUB 
 
9. USG KUB 
 
10. CT  KUB – grading  
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Treatment  
1. Fluids 
 
   
2. Antibiotics 
 
      
3. Dialysis – Peritoneal Dialysis/ Hemodialysis 
 
 
4. Percutaneous  drainage/ CT guided drainage/  Stenting 
 
 
5. Nephrectomy 
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1 Nagammal 50 F Y Y Y Y Y 9Yrs N N N 13600 178000 5 
Ni
l 
1.
2 
E.Coli 
Grown 
No 
Growth 
250 
1.
8 
7.4 
Ne
g 
NA
D 
Y 
Cla
ss 
II 
Piperacill
in plus 
tasobact
am and 
Insulin 
Periton
eal 
Dialysis 
Nil 
Surviv
ed 
2 Chandra 66 F N Y Y Y Y 
22Yr
s 
Y Y N 17400 69000 15 
P
os 
4.
5 
E.Coli 
Grown 
E.Coli 
Grown 
440 
5.
8 
9.2 
Ne
g 
NA
D 
Y 
Cla
ss 
III 
A 
Meropen
em and 
Insulin 
Hemo 
Dialysis 
Partial 
Nephrecto
my of right 
kidney 
Died 
3 Radhammal 46 F Y Y Y Y Y 7Yrs N N N 14300 189000 5 
Ni
l 
2.
7 
E.Coli 
Grown 
No 
Growth 
280 
2.
7 
8.6 
Ne
g 
NA
D 
Y 
Cla
ss 
II 
Impeinen 
and 
Insulin 
Periton
eal 
Dialysis 
Nil 
Surviv
ed 
4 Swamyk annu 65 M Y Y Y Y Y 
30Yr
s 
N N N 17600 42000 10 
P
os 
4.
7 
E.Coli 
Grown 
E.Coli 
Grown 
456 
4.
7 
9.9 
Ne
g 
NA
D 
Y 
Cla
ss 
III 
B 
Meropen
em, 
Ceftriaxo
ne and 
Insulin 
Hemo 
Dialysis 
CT guided 
drainage 
Died 
5 Ponnammal 48 F Y Y Y Y Y 7Yrs N N N 14600 174000 5 
Ni
l 
2.
2 
E.Coli 
Grown 
No 
Growth 
3 
01 
2.
3 
7.4 
Ne
g 
NA
D 
Y 
Cla
ss 
II 
Piperacill
in plus 
tasobact
am and 
Insulin 
Periton
eal 
Dialysis 
Nil 
Surviv
ed 
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6 Arokiya dass 72 M Y Y Y Y Y 
24Yr
s 
N Y 
Y
  
17400 47000 15 
P
os 
4.
6 
Klebsie
lla 
Grown 
Klebsie
lla 
Grown 
474 
6.
2 
10.
6 
Ne
g 
NA
D 
Y 
Cla
ss 
IIIB 
Meropen
em, 
Ceftriaxo
ne and 
Insulin 
Hemo 
Dialysis 
CT guided 
drainage 
Died 
7 Kaveri 47 F N Y Y Y Y 8Yrs N N N 12300 162000 5 
Ni
l 
2.
4 
E.Coli 
Grown 
No 
Growth 
306 
2.
4 
7.6 
Ne
g 
NA
D 
Y 
Cla
ss 
II 
Piperacill
in plus 
tasobact
am and 
Insulin 
Periton
eal 
Dialysis 
Nil 
Surviv
ed 
8 Saradhammal 72 F N Y Y Y Y 
25Yr
s 
N N N 18200 56000 15 
P
os 
4.
2 
Klebsie
lla 
Grown 
Klebsie
lla 
Grown 
448 
5.
9 
10.
6 
Ne
g 
NA
D 
Y 
Cla
ss 
III 
B 
Piperacill
in plus 
tasobact
am and 
Ceftriaxo
ne and 
Insulin 
Hemo 
Dialysis 
Nil Died 
9 Murugammal 52 F N Y Y Y Y 8Yrs N N N 13600 154000 10 
Ni
l 
2.
8 
E.Coli 
Grown 
No 
Growt
h 
298 
3.
2 
7.6 
Ne
g 
NA
D 
Y 
Cla
ss I 
Meropen
em and 
Insulin 
Periton
eal 
Dialysis 
Nil 
Surviv
ed 
10 Rose 58 F N Y Y Y Y 
7Yr
s 
N N N 
1380
0 
1820
00 
5 
N
il 
3
.
2 
E.Coli 
Grow
n 
No 
Grow
th 
26
8 
3.
9 
7.
5 
N
eg 
NA
D 
Y 
Cl
as
s I 
Ceftria
xone 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
11 Sidharthan 72 M N Y Y Y Y 
22Y
rs 
Y 
BP
H 
N 
Y 
Tu
rp 
do
ne  
1920
0 
5400
0 
2
0 
P
o
s 
4
.
2 
E.Coli 
Grow
n 
E.Coli 
Grow
n 
46
7 
7.
4 
9.
8 
N
eg 
NA
D 
Y 
Cl
as
s 
III 
A 
Merop
enem 
and 
Insulin 
Hemo 
Dialysi
s 
Partial 
Nephrec
tomy of 
right 
kidney 
Died 
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12 Parvathi 52 F Y Y Y Y Y 
9Yr
s 
N N N 
1420
0 
1400
00 
1
0 
N
il 
2
.
8 
E.Coli 
Grow
n 
No 
Grow
th 
25
7 
3.
6 
7.
8 
N
eg 
NA
D 
Y 
Cl
as
s II 
Piperac
illin 
plus 
tasoba
ctam 
and 
Ceftria
xone 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
13 
Kuttiyamm
al 
72 F Y Y Y Y Y 
20Y
rs 
N N N 
1820
0 
7000
0 
1
5 
P
o
s 
4
.
7 
Klebs
iella 
Grow
n 
Klebsi
ella 
Grow
n 
40
3 
7.
7 
9.
4 
N
eg 
NA
D 
Y 
Cl
as
s 
III
A 
Merop
enem, 
Vanco
mycin 
and 
Insulin 
Hemo 
Dialysi
s 
Nil Died 
14 Ammavasai 54 M N Y Y Y Y 
12Y
rs 
N N N 
1220
0 
1560
00 
1
0 
N
il 
2
.
4 
E.Coli 
Grow
n 
No 
Grow
th 
36
2 
2.
4 
7.
9 
N
eg 
NA
D 
Y 
Cl
as
s II 
Piperac
illin 
plus 
tasoba
ctam 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
15 Kumari 52 F Y N Y Y Y 
11Y
rs 
N N N 
1280
0 
1720
00 
5 
N
il 
2
.
8 
E.Coli 
Grow
n 
No 
Grow
th 
32
2 
2.
6 
7.
2 
N
eg 
NA
D 
Y 
Cl
as
s II 
Merop
enem 
and 
Insulin 
Hemo 
Dialysi
s 
Nil 
Survi
ved 
103 
 
16 Shanthi 57 F Y Y Y Y Y 
7Yr
s 
N N N 
1330
0 
2100
00 
1
0 
N
il 
2
.
6 
E.Coli 
Grow
n 
No 
Grow
th 
28
8 
3.
2 
7.
8 
N
eg 
NA
D 
Y 
Cl
as
s II 
Merop
enem 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
17 Abirami 58 F Y Y Y Y Y 
8Yr
s 
N N N 
1260
0 
1150
00 
8 
N
il 
1
.
6 
E.Coli 
Grow
n 
No 
Grow
th 
35
4 
2.
1 
7.
4 
N
eg 
NA
D 
Y 
Cl
as
s I 
Piperac
illin 
plus 
tasobe
ctam 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
18 Rasathi 62 F N Y Y N Y 
22Y
rs 
N N N 
1940
0 
4800
0 
1
5 
P
o
s 
4
.
1 
E.Coli 
Grow
n 
E.Coli 
Grow
n 
47
2 
8.
6 
9.
8 
N
eg 
NA
D 
Y 
Cl
as
s 
III
B 
Merop
enem 
and 
Insulin 
Hemo 
Dialysi
s 
Nil Died 
19 Anjalai 73 F Y Y Y Y Y 
20Y
rs 
N N N 
1920
0 
5200
0 
1
2 
P
o
s 
5
.
2 
Klebs
iella 
Grow
n 
Klebsi
ella 
Grow
n 
48
2 
6.
7 
9.
5 
N
eg 
NA
D 
Y 
Cl
as
s 
III 
B 
Piperac
illin 
plus 
tasoba
ctam 
and 
Ceftria
xone 
and 
Insulin 
Hemo 
Dialysi
s 
CT 
guided 
drainage 
Died 
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20 Perumal 54 M Y Y Y Y Y 
8Yr
s 
Y 
BP
H 
TU
RP 
don
e 
N 
Y 
Tu
rp 
do
ne  
1280
0 
1600
00 
4 
N
il 
2
.
4 
E.Coli 
Grow
n 
No 
Grow
th 
35
6 
1.
5 
7.
2 
N
eg 
NA
D 
Y 
Cl
as
s I 
Amikac
in and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
21 Arundathi 53 F N Y Y N Y 
4Yr
s 
N Y N 
1350
0 
1300
00 
2 
N
il 
3
.
6 
E.Coli 
Grow
n 
No 
Grow
th 
33
2 
4.
1 
7.
8 
N
eg 
NA
D 
Y 
Cl
as
s II 
Piperac
illin 
plus 
tasoba
ctam 
and 
Ceftria
xone 
and 
Insulin 
Hemo 
Dialysi
s 
Nephrec
tomy 
done 
Survi
ved 
22 Arunagiri 49 M N Y Y Y Y 
7Yr
s 
Y 
Uri
nar
y 
Stri
ctu
re 
N N 
1440
0 
1480
00 
7 
N
il 
2
.
6 
E.Coli 
Grow
n 
No 
Grow
th 
30
7 
3
2 
7.
2 
N
eg 
NA
D 
Y 
Cl
as
s II 
Merop
enem 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
23 
Punniyakot
ti 
56 F Y Y Y Y Y 
9Yr
s 
N N N 
1260
0 
1960
00 
5 
N
il 
2
.
2 
E.Coli 
Grow
n 
No 
Grow
th 
32
6 
3.
9 
8.
6 
N
eg 
NA
D 
Y 
Cl
as
s I 
Impein
en and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
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24 
Poongodha
i 
74 F Y Y Y Y Y 
24Y
rs 
N N N 
1960
0 
6200
0 
2
0 
P
o
s 
4
.
7 
Klebs
iella 
Grow
n 
Klebsi
ella 
Grow
n 
44
8 
7.
6 
9.
8 
N
eg 
NA
D 
Y 
Cl
as
s 
III 
A 
Piperac
illin 
plus 
tasoba
ctam 
and 
Ceftria
xone 
and 
Insulin 
Hemo 
Dialysi
s 
Nephrec
tomy 
done 
Died 
25 
Muthamm
al 
52 F Y Y Y Y Y 
8Yr
s 
N N N 
1230
0 
1740
00 
1
0 
N
il 
2
.
8 
E.Coli 
Grow
n 
No 
Grow
th 
34
7 
4.
2 
7.
4 
N
eg 
NA
D 
Y 
Cl
as
s I 
Merop
enem 
and 
Insulin 
Perito
neal 
Dialysi
s 
Nil 
Survi
ved 
 
 
